A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist
HemaSphere · 2026-10 · 10 (10)
DOI: 10.1002/hem3.70497 ↗Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 05.10.2026. Verfasst von Binje Vick und 45 weiteren Autor:innen. Beteiligte Einrichtung: Research Unit Apoptosis in Hematopoietic Stem Cells Helmholtz Munich, German Research Center for Environmental Health (HMGU) Munich Germany. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is a highly aggressive malignancy with poor prognosis, underlining the need for suitable model systems to develop novel treatments. To complement the few existing AML cell lines and restricted primografts, we transplanted more than 100 primary AML samples into immunocompromised mice and generated 23 exceptionally robust patient‐derived xenograft (*PDX) models of AML that allow virtually unlimited serial transplantation and efficient genetic engineering. These models represent individuals of all age groups and several WHO subgroups. *PDX models substantially outperform AML cell lines in preserving leukemia biology and include AML subgroups for which no cell lines exist, such as cytogenetically normal or IDH1/2 ‐mutant AML or simultaneous NPM1 mutation and FLT3‐ ITD. Their resilience to freeze‐thaw cycles supports broad dissemination across research institutions through sharing via CancerModels.org. Using lentiviruses, we stably expressed luciferase for longitudinal, noninvasive, and sensitive real‐time monitoring of leukemia burden and therapeutic response in vivo . This approach enabled rigorously controlled preclinical studies, including phase II‐like trials, which demonstrated highly variable treatment responses between different *PDX models, mimicking the heterogeneity in patient cohorts. Long‐term treatment, including repeated cytarabine exposure over 1 year, showed a yet undescribed decrease in leukemia's proliferation rate. These insights underscore the platform's distinctive capacity to study treatment dynamics over clinically relevant timeframes. Collectively, our unique resource represents a powerful, robust, and versatile platform with strong potential to accelerate translational AML research for the ultimate benefit of patients.
Autor:innen und Institutionen
- Research Unit Apoptosis in Hematopoietic Stem Cells Helmholtz Munich, German Research Center for Environmental Health (HMGU) Munich Germany.
- German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and University Hospital LMU Munich Munich Germany.
- Institute for Medical Information Processing, Biometry, and Epidemiology (IBE) LMU Medizin, LMU Munich Munich Germany.
- Department of Medicine III LMU University Hospital, LMU Medizin, LMU Munich Munich Germany.
- Hopp Children's Cancer Center Heidelberg (KiTZ) Heidelberg Germany.
- Manfred Fuchs Research Group Pediatric Leukemia Heidelberg University Hospital Heidelberg Germany.
ORCID-Profile: Binje Vick, Vindi Jurinovic, Kristina Kuhbandner, Lena Lagally, Lisa Latzko, Gerulf Hänel, Amelie Muth, Maximilian Schönung, Arnold Kloos, Lesca M Holdt, Dhruv Mehra, Johannes W Bagnoli, Maya C André, Claudia D Baldus, Martin Carroll, Martin Ebinger, Katharina S Götze, Pablo Menéndez, Christian Récher, Jean-Emmanuel Sarry, Christian Thiede, Talía Velasco-Hernández, Jan H Klusmann, Wolfgang Enard, Michael von Bergwelt-Baildon, Wolfgang Hiddemann, Klaus H Metzeler, Philipp A Greif, Michael Heuser, Daniel B Lipka, Marion Subklewe, Sebastian Vosberg, Tobias Herold, Karsten Spiekermann, Irmela Jeremias
Förderung
- European Research Council
- Deutsche Forschungsgemeinschaft
- Deutsche Krebshilfe
- Deutsche Kinderkrebsstiftung
- Joachim Herz Stiftung
Zitieren
APA
Vick, B., Jurinovic, V., Kuhbandner, K., Lagally, L., Latzko, L., Arnreich, C., Hänel, G., Muth, A., Schönung, M., Kloos, A., Rothenberg-Thurley, M., Dufour, A. M., Schneider, S., Holdt, L. M., Mura, L., Klein, F., Frank, A., Mehra, D., Fröhlich, A., …, & Jeremias, I. (2026). A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist. HemaSphere, 10(10). https://doi.org/10.1002/hem3.70497
Vancouver
Vick B, Jurinovic V, Kuhbandner K, Lagally L, Latzko L, Arnreich C, et al. A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist. HemaSphere. 2026;10(10). doi:10.1002/hem3.70497
BibTeX
@article{Vick2026,
author = {Vick, Binje and Jurinovic, Vindi and Kuhbandner, Kristina and Lagally, Lena and Latzko, Lisa and Arnreich, Chiara and Hänel, Gerulf and Muth, Amelie and Schönung, Maximilian and Kloos, Arnold and Rothenberg-Thurley, Maja and Dufour, Annika M and Schneider, Stephanie and Holdt, Lesca M and Mura, Liliana and Klein, Fabian and Frank, Annette and Mehra, Dhruv and Fröhlich, Annika and Bagnoli, Johannes W and André, Maya C and Baldus, Claudia D and Carroll, Martin and Dierks, Christine and Ebinger, Martin and Götze, Katharina S and Menéndez, Pablo and Récher, Christian and Sahal, Ambrine and Sarry, Jean-Emmanuel and Thiede, Christian and Velasco-Hernández, Talía and Wei, Xiaoyan and Klusmann, Jan H and Enard, Wolfgang and von Bergwelt-Baildon, Michael and Hiddemann, Wolfgang and Metzeler, Klaus H and Greif, Philipp A and Heuser, Michael and Lipka, Daniel B and Subklewe, Marion and Vosberg, Sebastian and Herold, Tobias and Spiekermann, Karsten and Jeremias, Irmela},
title = {A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist},
journal = {HemaSphere},
year = {2026},
volume = {10},
number = {10},
doi = {10.1002/hem3.70497}
}
EUVIMED